Health Equity in Rare Disease: The FDA Diversity Guidance Every Pharma Team Needs to Understand
Published: 05 Jun 2026
FDA diversity in clinical trials guidance raises the bar for sponsors across therapeutic areas — but the stakes are especially high in rare disease, where underrepresentation has compounded disparities for decades.
Health equity is not a checkbox. It requires infrastructure: trusted advocacy partnerships, culturally responsive engagement, and platforms that connect stakeholders who rarely sit at the same table.
Key implications for pharma teams
- Enrollment plans must demonstrate meaningful outreach to underrepresented groups
- Community engagement should begin before protocol finalization
- Supplier diversity and MBE partnerships can align procurement with mission
Building health equity infrastructure
Elevate Impact was built as health equity infrastructure for rare disease — starting with sickle cell disease and expanding to support cross-sector collaboration across the research lifecycle.
